Albo stock alert: halper sadeh llc is investigating whether the sale of albireo pharma, inc. is fair to shareholders

New york--( business wire )--halper sadeh llc, an investor rights law firm, is investigating whether the sale of albireo pharma, inc. (nasdaq: albo) to ipsen is fair to albireo shareholders. per the terms of the proposed transaction, ipsen would acquire albireo for $42.00 per share in cash plus one contingent value right per share (cvr), entitling its holder to deferred cash payments of $10.00 per cvr payable upon the u.s. food and drug administration's approval of bylvay in the biliary atresia indication by december 31, 2027.
ALBO Ratings Summary
ALBO Quant Ranking